Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Trading 07-24 12:50:13 EDT

3.11

+0.02

+0.65%

High3.12	Low2.99	Vol200.54K
Open3.07	D1 Closing3.09	Amplitude4.21%
Mkt Cap187.90M	Tradable Cap137.53M	Total Shares60.42M
T/O611.41K	T/O Rate0.45%	Tradable Shares44.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.11,"timestamp":1784911800301,"preClose":3.09,"halted":0,"volume":200535,"delay":0,"changeRate":0.00647249190938512,"floatShares":44221000,"shares":60416887,"eps":-1.979861,"marketStatus":"Trading","change":0.02,"latestTime":"07-24 12:50:13 EDT","open":3.07,"high":3.12,"low":2.99,"amount":611414.731023,"amplitude":0.042071,"askPrice":3.11,"askSize":500,"bidPrice":3.1,"bidSize":8100,"shortable":3,"etf":0,"ttmEps":-1.979861,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784923200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.09,"preHourTrading":{"tag":"盘前","latestPrice":3.2,"preClose":3.09,"latestTime":"08:41 EDT","volume":313,"amount":1001.0230784,"timestamp":1784896891424,"change":0.11,"changeRate":0.035599,"amplitude":0.064725},"postHourTrading":{"tag":"盘后","latestPrice":3.0517,"preClose":3.09,"latestTime":"19:34 EDT","volume":35089,"amount":108454.6571,"timestamp":1784849651222,"change":-0.0383,"changeRate":-0.012395,"amplitude":0.048188},"volumeRatio":0.50848,"impliedVol":0.6638,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/VYGR/","defaultTab":"news","newsList":[{"id":"2651060531","title":"Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed","url":"https://stock-news.laohu8.com/highlight/detail?id=2651060531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651060531?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:15","pubTimestamp":1784034900,"startTime":"0","endTime":"0","summary":"Biogen's Alzheimer's drug lowers toxic protein, but results were mixedAt 60 mg, diranersen slowed decline 26% on CDR-SB versus placeboLowest dose reduced decline on five of six common Alzheimer's asse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nL1N43A0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B19Z9P08.USD","VYGR","BIIB","BK4588","BK4585","BK4548","BK4139","DNLI","IE00B19Z9Z06.USD","LU0320765992.SGD","LU0234570918.USD","IE00B894F039.SGD","BK4535","BK4533","BMED","PBE","LU0889565916.HKD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170999","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Axsome Therapeutics (AXSM) and Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651170999?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:20","pubTimestamp":1784028024,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics (VYGR), Axsome Therapeutics (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-axsome-therapeutics-axsm-and-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-axsome-therapeutics-axsm-and-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AXSM","BK4505","LABU","NRIX","PTH","BK4588","BK4585","VYGR","BK4007","HCSG","XLV","BK4581","XBI","BK4137","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145087","title":"Voyager Therapeutics advances tau-silencing gene therapy program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145087?lang=en_us&edition=fundamental","pubTime":"2026-07-14 01:27","pubTimestamp":1783963636,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory prac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR","CNCR","SYNB","IBBQ","IBB","LFSC","BK4588","FBT","GNOM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651811118","title":"Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2651811118","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651811118?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:35","pubTimestamp":1783946140,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics  said Monday that it expects to begin its early Alzheimer's disease trial in adults in the second half of the year after the US Food and Drug Administration approved its investigational new drug application for VY1706 in June.The company said that toxicology data from its trial in non-human primates showed VY1706 gene therapy was well tolerated and resulted in sustained tau protein reduction of up to 75% in key brain regions following a single intravenous dose over six months.Voyager said that VY1706 demonstrated a favorable tolerability profile in the three- and six-month good laboratory practice toxicology study, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, and peripheral organs up to the highest dose tested.Shares of the company were up 3.2% in Monday's premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651746119","title":"Voyager Wins FDA IND Clearance for Alzheimer’s Gene Therapy Vy1706","url":"https://stock-news.laohu8.com/highlight/detail?id=2651746119","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651746119?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:11","pubTimestamp":1783944715,"startTime":"0","endTime":"0","summary":"Voyager wins FDA IND clearance for Alzheimer’s gene therapy VY1706Voyager Therapeutics received FDA IND clearance for VY1706, enabling a clinical trial in adults with early Alzheimer’s disease.Dosing ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL3Tv7Lp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651632119","title":"Voyager Demonstrates Single Iv Dose of Vy1706 Well Tolerated, Reduced Tau in 6-month Glp Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651632119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651632119?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:01","pubTimestamp":1783944060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA5R0VVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651930551","title":"Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651930551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651930551?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:00","pubTimestamp":1783922400,"startTime":"0","endTime":"0","summary":"Biogen's stock sank 8% in mid-May, after one of its experimental drugs for Alzheimer's disease missed a Phase 2 study's primary endpoint.On Tuesday, the biotech firm will show the first detailed data ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BMED","IONS","BIIB","IE00B19Z9P08.USD","LU0234570918.USD","LU0320765992.SGD","LU0109394709.USD","DNLI","BK4532","BK4139","BK4533","PBE","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4535","VYGR","ARWR","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649623753","title":"Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2649623753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649623753?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:35","pubTimestamp":1783334141,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, with a price target of $25.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379258","title":"Voyager Therapeutics Wins FDA IND Clearance for Alzheimer’s Gene Therapy Vy1706","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379258?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:03","pubTimestamp":1782734598,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics wins FDA IND clearance for Alzheimer’s gene therapy VY1706Voyager Therapeutics secured FDA IND clearance for Alzheimer’s gene therapy VY1706, enabling a clinical trial in adults w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL3ZDGKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014021.USD","BK4139","BK4112","BK4585","LU2095319765.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","VYGR","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646193808","title":"H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646193808","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646193808?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:36","pubTimestamp":1782390976,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, with a price target of $25.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-voyager-therapeutics-vygr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923164","title":"Voyager Therapeutics CEO to present fireside chat at H.C. Wainwright Neuro Perspectives conference webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923164","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923164?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:01","pubTimestamp":1781208076,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics CEO Alfred W. Sandrock Jr. will take part in a pre-recorded fireside chat at the H.C. Wainwright Neuro Perspectives Hybrid Conference.The webcast is scheduled to be available on-demand on June 15, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL2Dn88G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","VYGR","BK4588","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","LU2095319765.USD","BK4139","IE00BN0W2V16.EUR","NDAQ","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642828479","title":"Voyager Therapeutics Expands Authorized Shares After Stockholder Vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2642828479","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642828479?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:57","pubTimestamp":1781125022,"startTime":"0","endTime":"0","summary":"The latest update is out from Voyager Therapeutics ( ($VYGR) ). On June 9, 2026, Voyager Therapeutics, Inc. held its 2026 Annual Meeting of Stockho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642751164","title":"Voyager Therapeutics shareholders approve authorized share increase at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642751164","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642751164?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:06","pubTimestamp":1781122013,"startTime":"0","endTime":"0","summary":"Voyager held its 2026 annual shareholder meeting on June 9, 2026.Shareholders backed a charter amendment to lift authorized capital stock to 245 million shares from 125 million.The same amendment raised authorized common stock to 240 million shares from 120 million.The charter amendment was executed through a certificate of amendment filed on June 9, 2026, effective upon filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDLD1wyv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435726","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435726","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435726?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:30","pubTimestamp":1780939810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-ovid-therapeutics-ovid-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-ovid-therapeutics-ovid-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4585","ESTA","VYGR","BK4139","XLV","LU2324357040.USD","HCSG","BK4581","XBI","BK4137","BK4588","LABU","BK4198","OVID","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640300910","title":"Guggenheim Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640300910","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640300910?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:39","pubTimestamp":1780400369,"startTime":"0","endTime":"0","summary":"In a report released today, Debjit Chattopadhyay from Guggenheim maintained a Buy rating on Voyager Therapeutics, with a price target of $22.00. Ac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640443954","title":"Voyager Therapeutics announces FDA clearance for VY1706 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2640443954","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640443954?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:48","pubTimestamp":1780318109,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706, the company’s investig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-fda-clearance-for-vy1706-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-fda-clearance-for-vy1706-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","IND","VYGR","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895975","title":"Voyager Therapeutics says FDA clears IND for Alzheimer’s gene therapy VY1706","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895975","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640895975?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:04","pubTimestamp":1780315465,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics won FDA clearance of its IND for VY1706, a tau-silencing gene therapy for Alzheimer’s disease.Dosing in a multi-site, open-label, dose-escalation trial is expected to start in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4WPlY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995912","title":"Voyager Receives FDA Ind Clearance for Vy1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995912?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUABDQ4DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959220","title":"Voyager Therapeutics - to Initiate Vy1706 Clinical Trial in Adults With Early Alzheimer's; Dosing Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959220?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUABDQ4DX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064580","title":"Voyager Therapeutics’ Amy Quinlan, principal accounting officer, files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064580","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636064580?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:02","pubTimestamp":1779134520,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Principal Accounting Officer Amy Quinlan filed an initial ownership statement reporting 36,749 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbxSBfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.1649},{"period":"3month","weight":-0.1847},{"period":"6month","weight":-0.2275},{"period":"1year","weight":-0.0579},{"period":"ytd","weight":-0.2137}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.004281},{"month":2,"riseRate":0.545455,"avgChangeRate":0.057874},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037898},{"month":4,"riseRate":0.454545,"avgChangeRate":0.014405},{"month":5,"riseRate":0.636364,"avgChangeRate":0.040925},{"month":6,"riseRate":0.454545,"avgChangeRate":0.000781},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.027946},{"month":8,"riseRate":0.6,"avgChangeRate":-0.020662},{"month":9,"riseRate":0.2,"avgChangeRate":0.071458},{"month":10,"riseRate":0.3,"avgChangeRate":-0.010359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.07862},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.036226}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction